Biovica International AB Class B (SE:BIOVIC.B)
:BIOVIC.B
Want to see SE:BIOVIC.B full AI Analyst Report?
Top Page
Biovica International AB Class B
(BIOVIC.B)
Select Model
Select Model
Rating:44Neutral
Price Target:
kr0.35
▼(-0.57% Downside)
Action:Reiterated
Date:05/06/26
The score is held down primarily by weak financial performance (negative gross profit, large losses, and ongoing cash burn), with soft technical momentum reinforcing downside risk. A low-leverage balance sheet is a partial offset, but valuation signals remain constrained by negative earnings and no dividend data.
Positive Factors
Recurring consumable revenue
Biovica’s business model centers on consumable assay sales and testing services, creating recurring revenue as patients undergo repeated monitoring and labs adopt the DiviTum platform. This installed-base driven model supports predictable unit demand and long-term revenue per patient if clinical adoption continues.
Negative Factors
Negative gross profit
Negative gross profit indicates product costs and direct expenses currently exceed revenues, undermining unit economics. Persistent negative gross margins make sustainable profitability dependent on either substantial revenue scale, cost structure improvements, or pricing changes, which are multi-quarter challenges.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring consumable revenue
Biovica’s business model centers on consumable assay sales and testing services, creating recurring revenue as patients undergo repeated monitoring and labs adopt the DiviTum platform. This installed-base driven model supports predictable unit demand and long-term revenue per patient if clinical adoption continues.
Read all positive factors
Biovica International AB Class B (BIOVIC.B) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr93.57M
Dividend YieldN/A
Average Volume (3M)324.11K
Price to Earnings (P/E)―
Beta (1Y)1.02
Revenue Growth33.12%
EPS Growth64.71%
CountrySE
Employees26
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.50
Shares Outstanding277,487,200
10 Day Avg. Volume299,971
30 Day Avg. Volume324,106
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.50
Price to Sales (P/S)7.52
P/FCF Ratio-0.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.2
Revenue Forecast (FY)kr39.90M
Biovica International AB Class B Business Overview & Revenue Model
Company Description
Biovica International AB Class B (BIOVIC.B) is a biotechnology company based in Sweden, specializing in the development of diagnostic solutions for cancer. The company focuses on improving the management of cancer treatment through its innovative ...
How the Company Makes Money
Biovica generates revenue primarily by commercializing its diagnostic testing solutions based on the DiviTum platform. The company’s revenue model is principally tied to sales of test kits/assay consumables and related laboratory products used to ...
Biovica International AB Class B Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
62
Positive
Cash Flow
25
Negative
| Breakdown | TTM | Apr 2024 | Apr 2023 | Apr 2022 | Apr 2022 | Apr 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 10.90M | 8.62M | 7.29M | 3.38M | 2.04M | 2.08M |
| Gross Profit | -27.99M | 8.08M | 6.88M | 4.62M | 4.67M | 5.27M |
| EBITDA | -63.19M | -76.22M | -119.51M | -105.96M | -53.47M | -36.56M |
| Net Income | -71.50M | -87.62M | -124.82M | -110.49M | -60.00M | -39.48M |
Balance Sheet | ||||||
| Total Assets | 126.51M | 64.95M | 131.41M | 172.29M | 151.63M | 192.65M |
| Cash, Cash Equivalents and Short-Term Investments | 88.22M | 24.41M | 79.41M | 114.33M | 89.79M | 145.36M |
| Total Debt | 4.84M | 4.65M | 7.83M | 10.45M | 13.25M | 2.42M |
| Total Liabilities | 20.56M | 21.74M | 34.77M | 33.65M | 27.54M | 9.99M |
| Stockholders Equity | 105.95M | 43.21M | 96.64M | 138.63M | 124.09M | 182.66M |
Cash Flow | ||||||
| Free Cash Flow | -64.91M | -85.65M | -114.72M | -97.42M | -55.52M | -37.97M |
| Operating Cash Flow | -64.65M | -85.37M | -114.58M | -94.64M | -52.13M | -34.41M |
| Investing Cash Flow | -263.00K | -287.00K | -585.00K | -2.78M | -3.40M | -3.56M |
| Financing Cash Flow | 110.14M | 30.93M | 79.50M | 122.01M | -136.00K | 142.66M |
Biovica International AB Class B Technical Analysis
Negative
0.35
Price Trends
0.34
Negative
0.37
Negative
0.48
Negative
Market Momentum
>-0.01
Negative
45.58
Neutral
38.81
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BIOVIC.B, the sentiment is Negative. The current price of 0.35 is above the 20-day moving average (MA) of 0.33, above the 50-day MA of 0.34, and below the 200-day MA of 0.48, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 45.58 is Neutral, neither overbought nor oversold. The STOCH value of 38.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:BIOVIC.B.
Biovica International AB Class B Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | kr240.66M | 0.14 | -294.38% | ― | 57.22% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | kr76.16M | -2.76 | -21.31% | ― | -100.00% | 11.65% | |
44 Neutral | kr93.57M | -1.81 | -72.82% | ― | 33.12% | 64.71% | |
44 Neutral | kr125.65M | -1.48 | -52.45% | ― | -5.23% | 47.93% | |
42 Neutral | kr21.49M | -1.86 | -120.13% | ― | ― | 24.27% |
* Healthcare Sector Average
SE:BIOVIC.B
Biovica International AB Class B
0.32
-0.38
-54.34%
SE:ALZ
Alzinova AB
0.47
-1.33
-73.69%
SE:BIOSGN
Biosergen AB
9.65
-46.15
-82.71%
SE:NICA
Nanologica AB
0.66
-0.42
-38.52%
SE:NXTCL
NextCell Pharma AB
1.14
0.11
10.68%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.